PURPOSE: Radiation-induced pneumonitis (RP) is the most common dose-limiting complication in lung cancer patients treated with radiotherapy. Accumulating evidence indicates that P53 and the ataxia telangiectasia-mutated protein (ATM)-dependent signaling response cascade play a crucial role in radiation-induced diseases. Consistent with this, our previous study showed that a functional genetic ATM polymorphism was associated with increased RP risk. METHODS AND MATERIALS: To evaluate the role of genetic P53 polymorphism in RP, we analyzed the P53 Arg72Pro polymorphism in a cohort including 253 lung cancer patients receiving thoracic irradiation. RESULTS: We found that the P53 72Arg/Arg genotype was associated with increased RP risk compared with the 72Pro/Pro genotype. Furthermore, the P53 Arg72Pro and ATM -111G>A polymorphisms display an additive combination effect in intensifying the risk of developing RP. The cross-validation test showed that 63.2% of RP cases can be identified by P53 and ATM genotypes. CONCLUSIONS: These results indicate that genetic polymorphisms in the ATM-P53 pathway influence susceptibility to RP and genotyping P53 and ATM polymorphisms might help to identify patients susceptible to developing RP when receiving radiotherapy.
PURPOSE: Radiation-induced pneumonitis (RP) is the most common dose-limiting complication in lung cancerpatients treated with radiotherapy. Accumulating evidence indicates that P53 and the ataxia telangiectasia-mutated protein (ATM)-dependent signaling response cascade play a crucial role in radiation-induced diseases. Consistent with this, our previous study showed that a functional genetic ATM polymorphism was associated with increased RP risk. METHODS AND MATERIALS: To evaluate the role of genetic P53 polymorphism in RP, we analyzed the P53 Arg72Pro polymorphism in a cohort including 253 lung cancerpatients receiving thoracic irradiation. RESULTS: We found that the P53 72Arg/Arg genotype was associated with increased RP risk compared with the 72Pro/Pro genotype. Furthermore, the P53 Arg72Pro and ATM -111G>A polymorphisms display an additive combination effect in intensifying the risk of developing RP. The cross-validation test showed that 63.2% of RP cases can be identified by P53 and ATM genotypes. CONCLUSIONS: These results indicate that genetic polymorphisms in the ATM-P53 pathway influence susceptibility to RP and genotyping P53 and ATM polymorphisms might help to identify patients susceptible to developing RP when receiving radiotherapy.
Authors: Raymond H Mak; Brian M Alexander; Kofi Asomaning; Rebecca S Heist; Chen-yu Liu; Li Su; Rihong Zhai; Marek Ancukiewicz; Brian Napolitano; Andrzej Niemierko; Henning Willers; Noah C Choi; David C Christiani Journal: Cancer Date: 2011-12-05 Impact factor: 6.860
Authors: Chris R Kelsey; Isabel L Jackson; Scott Langdon; Kouros Owzar; Jessica Hubbs; Zeljko Vujaskovic; Shiva Das; Lawrence B Marks Journal: Clin Lung Cancer Date: 2013-01-10 Impact factor: 4.785
Authors: E-M Thurner; S Krenn-Pilko; U Langsenlehner; W Renner; A Gerger; K S Kapp; T Langsenlehner Journal: Strahlenther Onkol Date: 2014-01-16 Impact factor: 3.621
Authors: H Li; G Liu; L Xia; Q Zhou; J Xiong; J Xian; M Du; L Zhang; L Liao; X Su; Z Li; Q Luo; Y Cheng; T Zhang; D Wang; Z-Z Yang Journal: Br J Radiol Date: 2014-06-02 Impact factor: 3.039